Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM67OU4)

• Drug Name: ANAVEX 2-73 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]
Cognitive impairment	6D71	Phase 1	[2]
Infantile spasm	8A62.0	Phase 1	[1]
Parkinson disease	8A00.0	Phase 1	[1]
Rett syndrome	LD90.4	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 46932299
  CAS Number: CAS 195615-84-0
  TTD Drug ID: DM67OU4

Molecule-Related Drug Atlas

Drug(s) Targeting Muscarinic acetylcholine receptor M1 (CHRM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[4]
Fesoterodine fumarate	DM13495	Overactive bladder	GC50.0	Approved	[5]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[6]
Clidinium	DMUMQZ0	Abdominal stomach pain	DD91.4	Approved	[7]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[8]
Oxyphenonium	DMMQHOZ	Visceral spasms	MD81.4	Approved	[9]
Benztropine	DMGZOVN	Parkinson disease	8A00.0	Approved	[10]
Glycopyrrolate	DM2M3ZA	Anaesthesia	9A78.6	Approved	[11]
Pirenzepine	DMP6M1N	Peptic ulcer	DA61	Approved	[12]
Cycrimine	DM8C43Q	Parkinson disease	8A00.0	Approved	[13]

Drug(s) Targeting Opioid receptor sigma 1 (OPRS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dextromethorphan	DMUDJZM	Allergic rhinitis	CA08.0	Approved	[14]
Dextromethorphan Polistirex	DMEHCY5	Dry cough	MD12	Approved	[15]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[16]
AVP-786	DMV1SOR	Alzheimer disease	8A20	Phase 3	[17]
ADX N05	DMLBYRA	Mood disorder	6A60-6E23	Phase 3	[18]
Igmesine	DMH97XA	Major depressive disorder	6A70.3	Phase 2	[19]
OPC-14523	DMB1WF3	Bulimia nervosa	6B81	Phase 2	[20]
SSR-125047	DMSUFW6	Schizophrenia	6A20	Phase 1	[21]
SA-5845	DM6XZRL	Central nervous system disease	8A04-8D87	Phase 1	[22]
SSR-125329A	DMG6NI8	Immune System disease	4A01-4B41	Phase 1	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M1 (CHRM1)	TTZ9SOR	ACM1_HUMAN	Agonist	[1]
Opioid receptor sigma 1 (OPRS1)	TT5TPI6	SGMR1_HUMAN	Agonist	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] 2011 Pipeline of Anavex.
• [4] Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
• [7] Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
• [8] The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
• [9] Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
• [10] Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
• [11] Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
• [12] Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
• [13] Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
• [14] Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [17] Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
• [18] Clinical pipeline report, company report or official report of SK BioPhamaceuticals.
• [19] Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19.
• [20] Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
• [21] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [22] Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45.
• [23] SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties. Eur J Pharmacol. 2002 Dec 5;456(1-3):123-31.